Format

Send to

Choose Destination
Cell Stem Cell. 2014 Feb 6;14(2):141-5. doi: 10.1016/j.stem.2014.01.013.

MSC-based product characterization for clinical trials: an FDA perspective.

Author information

1
Office of the Commissioner (OC), Office of the Chief Scientist (OCS), Office of Regulatory Science and Innovation (ORSI), 10903 New Hampshire Boulevard, Silver Spring, MD 20993, USA; Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapy (OCTGT), Division of Cell and Gene Therapy (DCGT), 1401 Rockville Pike, Rockville, MD 20852, USA. Electronic address: m.mendicino.phd@gmail.com.
2
CBER, OCTGT, Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), 1401 Rockville Pike, Rockville, MD 20852, USA.
3
Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapy (OCTGT), Division of Cell and Gene Therapy (DCGT), 1401 Rockville Pike, Rockville, MD 20852, USA.
4
Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapy (OCTGT), Division of Cell and Gene Therapy (DCGT), 1401 Rockville Pike, Rockville, MD 20852, USA. Electronic address: steven.bauer@fda.hhs.gov.

Abstract

Proposals submitted to the FDA for MSC-based products are undergoing a rapid expansion that is characterized by increased variability in donor and tissue sources, manufacturing processes, proposed functional mechanisms, and characterization methods. Here we discuss the diversity in MSC-based clinical trial product proposals and highlight potential challenges for clinical translation.

PMID:
24506881
DOI:
10.1016/j.stem.2014.01.013
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center